This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Abstract Details

Activity Number: 18
Type: Topic Contributed
Date/Time: Sunday, August 1, 2010 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract - #306419
Title: Novel Phase I Design for Oncology Research
Author(s): Linda Sun*+ and Keaven M. Anderson and Lisa Lupinacci and Yevgen Tymofyeyev
Companies: Merck & Co., Inc. and Merck Research Laboratories and Merck & Co., Inc. and Merck & Co., Inc.
Address: , , PA, 19446, USA
Keywords: Phase I oncology ; Bayesian ; Adaptive

The primary objective of Phase I oncology studies is to identify a dose with an acceptable toxicity rate to move into Phase II efficacy studies. Various Phase I oncology designs have been proposed in the past, from the simplest 3+3 design to the more complex continuous reassessment method (CRM). In this talk, we will introduce an easy-to-implement Bayesian adaptive design which makes dose escalation or de-escalation based on the posterior probability of the toxicity rate at the dose level currently being tested. Simulation results show that this novel design out-performs the 3+3 design with higher probability of choosing the dose with the targeted toxicity rate. It slightly under-performs the CRM design. However, this design can show the dose escalation rules in a simple table before the study starts. This feature is very appealing to physician, regulatory reviewers, and IRBs.

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2010 program

2010 JSM Online Program Home

For information, contact or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.